EPO Patents = 4

Trademarks = 2

Forward Citations = 41

Loading Chart...

7 inventors (with patents filed for the assignee):

Carlos A Schuler (11 out of 23 patents)

Luiz Belardinelli (8 out of 43 patents)

Rangachari Narasimhan (8 out of 8 patents)

4. Prashanti Madhavapeddi (4 out of 4 patents)

5. Michael Laird Hurrey (3 out of 6 patents)

6. Gregory Marcus (2 out of 3 patents)

7. Miguel Guzman (2 out of 2 patents)

13 patents: Sort by Forward Citations

1. 12576074 - Kits and methods for induction of cardioversion in subjects with atrial arrhythmias (2026-03-17),

2. 12576073 - Antiarrhythmic formulation (2026-03-17),

3. 12059414 - Kits and methods for induction of cardioversion in subjects with atrial arrhythmias (2024-08-13),

4. 11547663 - Unit aerosol doses for anticoagulation (2023-01-10),

5. 11020384 - Antiarrhythmic formulation (2021-06-01),

6. 11007185 - Antiarrhythmic formulation (2021-05-18),

7. 10744087 - Method to slow ventricular rate (2020-08-18),

8. 10668015 - Unit aerosol doses for anticoagulation (2020-06-02),

9. 10660578 - Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation (2020-05-26),

10. 10441537 - Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration (2019-10-15),

11. 10045939 - Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration (2018-08-14),

12. 10010294 - Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation (2018-07-03),

13. 8974828 - Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration (2015-03-10),

Company Overview

Incarda Therapeutics, Inc. is a biopharmaceutical company based in Newark, California, focused on developing innovative therapies for cardiovascular diseases. The company specializes in advanced drug delivery systems that aim to enhance the efficacy and safety of treatments for heart conditions. With a commitment to addressing unmet medical needs, Incarda leverages cutting-edge research and technology to create solutions that improve patient outcomes and quality of life in the cardiovascular space.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

13 Patents

#31 in Newark, CA

#5,656 in California

#23,838 in US

#45,039 in the World

Newark, CA, United States of America

Incarda Therapeutics, Inc.

Forward Citations = 41

7 inventors:

Carlos A Schuler (11 out of 23 patents)

Luiz Belardinelli (8 out of 43 patents)

Rangachari Narasimhan (8 out of 8 patents)

4. Prashanti Madhavapeddi (4 out of 4 patents)

5. Michael Laird Hurrey (3 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Incarda Therapeutics, Inc.. Retrieved from https://idiyas.com/company/incarda-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

4 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]